Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo
Clinical trial NCT02798211 · COMPLETED
Trial details
- NCT number
- NCT02798211
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2016-06-27
- Primary completion
- 2018-12-05
- Enrollment
- 258
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.